Answers are grounded in this paper and cite their sources.
Diabetic foot ulcer (DFU) is a leading cause of disability and mortality in patients with diabetes, with recurrence rates exceeding 40% despite current standard of care. A persistent imbalance between pro-inflammatory M1 and reparative M2 macrophages is now recognized as a central immunological feature of the refractory DFU wound bed. Exosomes, nanoscale extracellular vesicles that carry nucleic acids and proteins from their parent cells, can restore this polarization balance and promote wound closure in preclinical models. This review summarizes evidence on the DFU microenvironment and on the mechanisms that drive macrophage polarization dysregulation, including hyperglycemia-induced metabolic reprogramming, advanced glycation end product accumulation, reactive oxygen species overload, and bacterial biofilm colonization. We then compare the immunomodulatory effects of exosomes derived from mesenchymal stem cells, adipose-derived stem cells, platelet-rich plasma, and plant-derived exosome-like nanovesicles on macrophage polarization, and examine the underlying molecular mechanisms at three levels: non-coding RNA-mediated post-transcriptional regulation, signaling pathway modulation (NF-κB, MAPK, STAT6, PI3K/AKT, NLRP3), and metabolic and epigenetic reprogramming. We also evaluate responsive hydrogel delivery systems (pH-, glucose-, enzyme-, and ROS-responsive) that prolong exosome retention and allow controlled release, and assess the clinical translation pipeline, in which robust preclinical findings are now met by limited but emerging first-in-human evidence. Standardized manufacturing, dose optimization, and regulatory clarity remain the main hurdles to clinical application.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: